The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial

PURPOSE: To investigate the efficacy and safety of the novel orally active PI3Kδ inhibitor in relapsed and/or refractory patients with follicular lymphoma (FL) who had received at least two prior systemic treatments. PATIENTS AND METHODS: Histologically confirmed relapsed and/or refractory patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Tingyu, Sun, Xiuhua, Qiu, Lihua, Su, Hang, Cao, Junning, Li, Zhiming, Song, Yuqin, Zhang, Li, Li, Dengju, Wu, Huijing, Zhang, Wei, Li, Junmin, Zhou, Keshu, Zhou, Hui, Yang, Yu, Li, Zhifeng, Cen, Hong, Cai, Zhen, Zhang, Zhihui, Fu, Weijun, Jin, Jie, Li, Fei, Wu, Weixin, Gu, Xuekui, Zhu, Weiliang, Liu, Lihong, Li, Zengjun, Yi, Shuhua, Bao, Hanying, Xu, Zusheng, Qiu, Lugui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102838/
https://www.ncbi.nlm.nih.gov/pubmed/36735519
http://dx.doi.org/10.1158/1078-0432.CCR-22-2939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102838/
https://www.ncbi.nlm.nih.gov/pubmed/36735519
http://dx.doi.org/10.1158/1078-0432.CCR-22-2939

Ejemplares similares